for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

OncoTherapy Science, Inc.

4564.T

Latest Trade

90.00JPY

Change

1.00(+1.12%)

Volume

144,200

Today's Range

89.00

 - 

90.00

52 Week Range

89.00

 - 

173.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

OncoTherapy Science unit signs research collaboration agreement to accelerate the Cancer Precision Medicine

Aug 9 (Reuters) - OncoTherapy Science Inc <4564.T>:Says the company hereby announces that, aiming to accelerate the Cancer Precision Medicine, unit Cancer Precision Medicine, Inc. (CPM) has agreed on a research collaboration with SECOM Medical System Co., Ltd. and Yotsuya Medical Cube about liquid biopsy study for the early detection of cancer.

OncoTherapy Science unit says joint development with Japanese Foundation For Cancer Research

March 1 (Reuters) - OncoTherapy Science Inc <4564.T>:Says co's unit Cancer Precision Medicine signs joint development agreement with Japanese Foundation For Cancer Research.Says two entities will cooperate on development of genetic variation in cancer .

OncoTherapy Science unit says business alliance with Thermo Fisher Scientific

Feb 15 (Reuters) - OncoTherapy Science Inc <4564.T>:Says its unit, Cancer Precision Medicine forms business alliance with Thermo Fisher Scientific .Says two entities mainly cooperate on evaluation of liquid biopsy platform based on Ion Torrent Oncomine Pan-Cancer Cell-Free Assay .

OncoTherapy Science says close of peptide vaccine related agreement with ONO PHARMACEUTICAL

Aug 2 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says peptide vaccine related agreement with.

OncoTherapy Science receives patent in Japan

July 13 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says it received a patent (No.6159948 )for MELK specific inhibitors in Japan.

OncoTherapy Science says business and capital alliance with Theragen Etex

July 12 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says it will establish a wholly owened subsidary on July 24.* Say it will transfer research and development of cancer immunotherapy related business to the subsidiary, effective Nov. 1 .* The subsidary will issue 150 new shares to Theragen Etex Co., Ltd. <066700.KQ>, at the price of 1 million yen per share, or 150 million yen in total, and payment date on Aug. 7 .* Theragen Etex Co., Ltd. will acquire 310 shares of the subsidiary, at the price of 1 million yen, for 310 million yen in total, from the co, effective Nov. 15 .* Say the co and Theragen Etex Co., Ltd. Will hold a 64 percent stake and a 36 percent stake finally .

OncoTherapy Science announces change of president

OncoTherapy Science Inc <4564.T> : Says co appoints Kazuo Yamamoto as new president, replacing Masaharu Mori who resigns .Change will be effective on Feb. 27.

OncoTherapy Science says result of phase I clinical trial of OTS103/104 (OCV-C02)

OncoTherapy Science Inc <4564.T>: Says Phase 1 trial of OCV-C02, a peptide vaccine for metastatic colorectal cancer patients refractory to all standard chemotherapies .Says OCV-C02 at 0.3 to 6 mg/body exhibited a safe and well tolerated profile, and showed immunological responses in mCRC pts refractory to all standard chemotherapies.

Onco Therapy Science to start Phase I clinical study for breast cancer patients in U.S.

Onco Therapy Science Inc <4564.T>:Says the co will conduct Phase I clinical study of OTS167, a MELK specific inhibitor, for breast cancer patients following the acceptance of the protocol by the U.S. Food and Drug Administration.

OncoTherapy Science says first-patient enrollment in Phase I/II clinical study of OTS167

OncoTherapy Science Inc <4564.T>:Says the first patient has been enrolled in Phase I/II clinical study of OTS167, an MELK-specific inhibitor, for Acute Myeloid Leukemia.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up